Year 6

(1) We have validated a new type of T cell immunotherapy using iPSC-reprogramming technology, and spun out a company to translate this into clinical therapy.

(2) We have developed new culture conditions to better grow blood-forming stem cells and other immune cell types ex vivo. 

(3) We have improved the technology for generating whole organs from iPSCs via blastocyst complementation.